EcoDrugPlus

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSOKIG00005008747
Gene Symbol: FGFR1A
1 Cross references
203 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSOKIG00005015147
Gene Symbol: FGFR2
1 Cross references
213 Possible Orthologues:

Fibroblast Growth Factor Receptor 2-Like

Ensembl ID : ENSOKIG00005029633
Gene Symbol: LOC109865572
3 Cross references
213 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSOKIG00005028463
Gene Symbol: FGFR3
1 Cross references
191 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSOKIG00005007728
Gene Symbol: FLT1
1 Cross references
192 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSOKIG00005021987
Gene Symbol: FLT1
1 Cross references
192 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSOKIG00005008384
Gene Symbol: FLT3
3 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSOKIG00005017223
Gene Symbol: FLT4
1 Cross references
185 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSOKIG00005035303
Gene Symbol: FLT4
1 Cross references
186 Possible Orthologues:

Folate Receptor Beta

Ensembl ID : ENSOKIG00005009968
Gene Symbol: FOLR2
3 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSOKIG00005026200
Gene Symbol: FSHR
1 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 2

Ensembl ID : ENSOKIG00005015271
Gene Symbol: LOC109901483
2 Cross references
299 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).